Revenue growth remains tepid at 1.9% as of 2026Q1, while operating margins exhibit extreme volatility, swinging from a negative 38.6% in 2024Q3 to 11.1% in the most recent quarter.
| Sales/Revenue | 1.06B | 1.06B | 1.03B | 1.05B | 1.07B | 1.11B | 1.08B |
| Revenue Growth % | 3.16% | 2.44% | -1.1% | -2.32% | -3.21% | 2.63% | - |
| Cost of Goods Sold | 554.5M | 562.7M | 530.8M | 535.6M | 525.6M | 513.9M | 537.5M |
| COGS % of Revenue | - | 53.08% | 51.29% | 51.19% | 49.07% | 46.44% | 49.85% |
| Gross Profit | 510.4M | 497.3M | 504M | 510.7M | 545.5M | 592.7M | 540.7M |
| Gross Margin % | 47.93% | 46.92% | 48.71% | 48.81% | 50.93% | 53.56% | 50.15% |
| Gross Profit Growth % | - | -1.33% | -1.31% | -6.38% | -7.96% | 9.62% | - |
| Operating Expenses | 433.2M | 433.5M | 619.1M | 558.3M | 556.9M | 449.8M | 438M |
| OpEx % of Revenue | - | 40.9% | 59.83% | 53.36% | 51.99% | 40.65% | 40.62% |
| Selling, General & Admin | 422.7M | 433.5M | 425.9M | 441.6M | 414.9M | 412.9M | 398M |
| SG&A % of Revenue | - | 40.9% | 41.16% | 42.21% | 38.74% | 37.31% | 36.91% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 2M | 0 | 193.2M | 116.7M | 142M | 36.9M | 40M |
| Operating Income | 77.2M | 63.8M | -115.1M | -47.6M | -11.4M | 142.9M | 102.7M |
| Operating Margin % | 7.25% | 6.02% | -11.12% | -4.55% | -1.06% | 12.91% | 9.53% |
| Operating Income Growth % | - | 155.43% | -141.81% | -317.54% | -107.98% | 39.14% | - |
| EBITDA | 98M | 86.3M | -83.6M | -16.7M | 21.6M | 179.8M | 142.7M |
| EBITDA Margin % | 9.2% | 8.14% | -8.08% | -1.6% | 2.02% | 16.25% | 13.23% |
| EBITDA Growth % | 219.37% | 203.23% | -400.6% | -177.31% | -87.99% | 26% | - |
| D&A (Non-Cash Add-back) | 20.8M | 22.5M | 31.5M | 30.9M | 33M | 36.9M | 40M |
| EBIT | 35.9M | 63.8M | -115.1M | -47.4M | -10.5M | 148.3M | 105.4M |
| Net Interest Income | -30.8M | -33.8M | -42.9M | -43M | -15M | -300K | -5.2M |
| Interest Income | 3.8M | 200K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 34.6M | 34M | 42.9M | 43M | 15M | 300K | 5.2M |
| Other Income/Expense | -72.2M | -62.4M | -42.9M | -42.8M | -14.1M | 5.1M | -2.5M |
| Pretax Income | 5M | 1.4M | -158M | -90.4M | -25.5M | 148M | 100.2M |
| Pretax Margin % | 0.47% | 0.13% | -15.27% | -8.64% | -2.38% | 13.37% | 9.29% |
| Income Tax | 6.1M | 4M | -4M | -11.4M | 12.8M | 35.1M | 24.4M |
| Effective Tax Rate % | 122% | 285.71% | 2.53% | 12.61% | -50.2% | 23.72% | 24.35% |
| Net Income | -3.2M | -4.6M | -156.2M | -80.5M | -40.4M | 111.1M | 75M |
| Net Margin % | -0.3% | -0.43% | -15.09% | -7.69% | -3.77% | 10.04% | 6.96% |
| Net Income Growth % | 97.69% | 97.06% | -94.04% | -99.26% | -136.36% | 48.13% | - |
| Net Income (Continuing) | -1.1M | -2.6M | -154M | -79M | -38.3M | 112.9M | 75.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 30.4M | 30.1M | 30.4M | 32M | 33.6M | 13.3M | 6.7M |
| EPS (Diluted) | -0.06 | -0.09 | -3.11 | -1.61 | 1.25 | 28.49 | 19.23 |
| EPS Growth % | 97.12% | 97.09% | -93.17% | -228.8% | -95.61% | 48.15% | - |
| EPS (Basic) | - | -0.09 | -3.11 | -1.61 | 1.25 | 28.49 | 19.23 |
| Diluted Shares Outstanding | 52.9M | 50.8M | 50.2M | 49.9M | 50.1M | 3.9M | 3.9M |
| Basic Shares Outstanding | 51.2M | 50.8M | 50.2M | 50.05M | 50.1M | 3.9M | 3.9M |
| Dividend Payout Ratio | - | - | - | - | - | 138.7% | 192.67% |
Medicare Advantage reimbursement compression
As indicated by the most recent quarterly filings, Enhabit's top-line growth remains tepid, with revenue expanding by only 1.9% in 2026Q1, reflecting the ongoing difficulty of scaling volume in a market increasingly dominated by lower-reimbursing Medicare Advantage plans rather than traditional fee-for-service Medicare.
The company's revenue trajectory appears constrained by the structural shift in payer mix, which limits the ability to drive meaningful top-line expansion through pricing. Investors should monitor whether the current volume growth is sufficient to offset the persistent downward pressure on revenue per episode.
Based on reported financial statements, Enhabit's gross margin has fluctuated between 45.8% and 49.9% over the last ten quarters, suggesting that the company struggles to maintain consistent profitability in the face of rising clinical labor costs and unpredictable reimbursement rates from federal and private payers.
The variability in gross margins implies that the company lacks the pricing power to fully pass through labor inflation to its payers. This instability warrants further investigation into whether the company's clinical staffing model is sufficiently flexible to adapt to changing reimbursement environments.
According to historical income statement data, Enhabit's operating margin has shown extreme volatility, swinging from a negative 38.6% in 2024Q3 to a positive 11.1% in 2026Q1, which highlights the company's inability to consistently scale its administrative overhead relative to its gross profit generation.
The erratic nature of operating income suggests that the company's SG&A structure is not yet optimized for a standalone public entity. The lack of consistent operating leverage may indicate that fixed costs remain disproportionately high relative to the current revenue base.
As evidenced by the significant swings in net income, including a $38.7 million loss in 2025Q4 followed by a $19.2 million profit in 2026Q1, the quality of reported earnings appears compromised by non-operating items and the ongoing costs associated with the company's post-spin-off operational restructuring.
The frequent divergence between operating income and net income suggests that investors should be cautious when relying on headline EPS figures. The impact of stock-based compensation, which reached $6.8 million in 2025Q4, further complicates the assessment of true underlying profitability.
While some may argue that Enhabit's hospice licenses provide a valuation floor, the persistent negative net margins observed in several recent quarters suggest that the core home health business may be fundamentally challenged by a structural ceiling on reimbursement rates that management cannot easily overcome.
Short-term improvements in profitability may be masking deeper issues related to the company's reliance on high-cost contract labor. If the company fails to stabilize its operating margins, the current valuation may continue to reflect market skepticism regarding its long-term viability as an independent entity.
Quick answers to the most common questions about buying EHAB stock.
For fiscal year 2025, Enhabit, Inc. (EHAB) reported total revenue of $1.06B. This represents a 1.7% decline compared to $1.08B in 2020.
Enhabit, Inc. (EHAB) reported a net loss of $4.6M for the fiscal year ending 2025.
Enhabit, Inc. (EHAB) reported an operating income of $63.8M, resulting in an operating profit margin of 6.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Enhabit, Inc. (EHAB) generated $497.3M in gross profit for the year, representing a gross profit margin of 46.9%. This demonstrates the company's core pricing power and production efficiency.